Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Share-based Compensation (2020 - 2021)

Design Therapeutics' Share-based Compensation history spans 2 years, with the latest figure at $1.6 million for Q4 2021.

  • For Q4 2021, Share-based Compensation rose 269.6% year-over-year to $1.6 million; the TTM value through Dec 2021 reached $4.7 million, up 942.0%, while the annual FY2025 figure was $14.5 million, 11.3% up from the prior year.
  • Share-based Compensation for Q4 2021 was $1.6 million at Design Therapeutics, up from $1.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.6 million in Q4 2021 and bottomed at $4000.0 in Q1 2020.